in Health

PET imaging validates use of common cholesterol drug to enhance HER2-targeted cancer therapy

1.7k Views

Pet imaging validates use of common cholesterol drug to enhance HER2-targeted cancer therapy

Representative PET images of 89ZrDFO-trastuzumab displaying %ID/g acquired 48 hours after radiolabeled trastuzumab injection on day 39 for T-DM1 single-treatment regime, T-DM1/statin single-treatment regime, T-DM1 multiple-treatment regime, and T-DM1/statin multiple-treatment regime. Tumor location is indicated by arrow. Credit: Journal of Nuclear Medicine (2023). DOI:…

Read the full article


Posted by Editor

JD.com Warns Consumer Recovery Months Away

JD.com Sinks to Record Low as Wall Street Brokers Turn Bearish
sand timer

Always late? You might be a ‘time optimist’ — here’s how to be more punctual